Latest filing published 04 Jun 2020 for GT Biopharma, Inc., €3,784.
Filing timeline
BuySaleInsider track record
Tony Cataldo: trading record in brief
This profile gathers the share dealings of Tony Cataldo across 2 companies, led by GT Biopharma, Inc. and Iovance Biotherapeutics, Inc. Between 6 May 2011 and 2 June 2020, the trades on record add up to 8 filings.
Every open-market trade on record is a sale: 2 sales worth €4,485. Other entries cover 3 share grants. Since January 2020: no purchases and 1 sale on the market.
Most recently, on 4 June 2020, the filings show an open-market sale worth €3,784 in GT Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 18 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Tony Cataldo
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,234,320 shares@ US$0.001100.0% of flowcommon stockSEC:0000939798-20-000007:0
- 7,000,000 shares0common stockSEC:0000939798-19-000031:0
- 800,000 shares@ US$0.00115.6% of flowcommon stockSEC:0000939798-19-000005:0
- 3,000,000 shares0common stockSEC:0000939798-17-000102:3
- 5,129,660 shares0common stockSEC:0000939798-17-000102:0
- 200,000 shares0common stockSEC:0000939798-17-000102:1
- 100,000 shares0common stockSEC:0000939798-17-000102:2
- 3,000,000 shares@ US$1.23Common StockSEC:0001513160-11-000023:0
8 of 8 declarations
